Polymerase News and Research

RSS

SARS-CoV-2 Omicron less pathogenic in hamsters

A new research paper posted as a preprint to the bioRxiv* server attempts to throw some light on this question by studying viral pathogenicity in golden hamsters, a valuable model for severe COVID-19 due to the development of reproducible weight loss and pneumonia after infection with the virus.

6 Jan 2022

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

Researchers investigate SARS-CoV-2 antigenic drift by evaluating the neutralizing activity of sera from patients infected with all five SARS-CoV-2 VOCs.

6 Jan 2022

How effective are COVID-19 vaccines against the Omicron and Delta variants?

Researchers study the effectiveness of COVID-19 vaccines against the SARS-CoV-2 Omicron and Delta variants.

6 Jan 2022

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

Emergence of a new SARS-CoV-2 variant from Southern France

A new study has described the emergence of another new SARS-CoV-2 variant from south-eastern France with Cameroonian origin.

6 Jan 2022

Host kinase identified as an inhibition target for SARS-CoV-2

In this experiment, the chemical probe SGC-CK2-1 inhibited virus replication at nanomolar concentration, showing a highly selective effect on the kinase.

6 Jan 2022

SARS-CoV-2 appears to persist in organs throughout the body for months

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate.

6 Jan 2022

Scientists estimate transmission advantage of Omicron over Delta variant as +105%

Researchers use statistical models to assess the transmission of the SARS-CoV-2 Omicron using variant-specific screening tests and genome sequencing.

5 Jan 2022

Comparison of the mutational profile of Omicron with other SARS-CoV-2 lineages

Researchers from nference labs in Massachusetts have been examining the origins of a particular mutation in the Omicron variant.

5 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

Study suggests increased vaccine breakthrough for SARS-CoV-2 Omicron variant in Houston, Texas

A recent study reveals early signals of substantially increased vaccine breakthrough for the Omicron variant of SARS-CoV-2 in Houston, Texas.

4 Jan 2022

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

A new research letter assessed patients hospitalized with a positive SARS-CoV-2 test during the fourth wave compared to the previous waves.

4 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

Researchers use data and a mathematical model to determine the impact of the SARS-CoV-2 Omicron variant on future risk of infection.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Omicron surges in England especially in young

Researchers used data from the REACT-1 study to analyze SARS-CoV-2 community prevalence and the emergence of the Omicron variant in England.

3 Jan 2022

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

New evidence implies that the Omicron variant may cause a less severe and/or faster recovery from clinical COVID-19 disease.

31 Dec 2021

SARS-CoV-2 omicron variant may be less severe than the delta variant

A new study reveals that omicron infections in South Africa are associated with lower rates of hospital admissions and lower disease severity compared to beta and delta infections.

31 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Polymerase News and Research

SARS-CoV-2 Omicron less pathogenic in hamsters

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

How effective are COVID-19 vaccines against the Omicron and Delta variants?

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

Emergence of a new SARS-CoV-2 variant from Southern France

Host kinase identified as an inhibition target for SARS-CoV-2

SARS-CoV-2 appears to persist in organs throughout the body for months

Scientists estimate transmission advantage of Omicron over Delta variant as +105%

Comparison of the mutational profile of Omicron with other SARS-CoV-2 lineages

Israeli study confirms drop in BNT162b2 efficacy after six months

Study suggests increased vaccine breakthrough for SARS-CoV-2 Omicron variant in Houston, Texas

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Omicron surges in England especially in young

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

SARS-CoV-2 omicron variant may be less severe than the delta variant

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News